PMID- 36385246
OWN - NLM
STAT- MEDLINE
DCOM- 20230224
LR  - 20230413
IS  - 2240-2993 (Electronic)
IS  - 0300-9009 (Print)
IS  - 0300-9009 (Linking)
VI  - 123
IP  - 1
DP  - 2023 Feb
TI  - A review of the potential neurological adverse events of COVID-19 vaccines.
PG  - 9-44
LID - 10.1007/s13760-022-02137-2 [doi]
AB  - Despite the advantages of getting access to the coronavirus disease 2019 
      (COVID-19) vaccines, their potential ability to induce severe adverse events 
      (AEs) has been a significant concern. Neurological complications are significant 
      among the various adverse events following immunization (AEFI) due to their 
      likely durability and debilitating sequelae. Neurological AEs following COVID-19 
      vaccination can either exacerbate or induce new-onset neuro-immunologic diseases, 
      such as myasthenia gravis (MG) and Guillain-Barre syndrome (GBS). The more severe 
      spectrum of AEs post-COVID19 vaccines has included seizures, reactivation of the 
      varicella-zoster virus, strokes, GBS, Bell's palsy, transverse myelitis (TM), and 
      acute disseminated encephalomyelitis (ADEM). Here, we discuss each of these 
      neurological adverse effects separately.
CI  - (c) 2022. The Author(s) under exclusive licence to Belgian Neurological Society.
FAU - Mohseni Afshar, Zeinab
AU  - Mohseni Afshar Z
AD  - Clinical Research Development Center, Imam Reza Hospital, Kermanshah University 
      of Medical Sciences, Kermanshah, Iran.
FAU - Sharma, Akanksha
AU  - Sharma A
AD  - Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.
FAU - Babazadeh, Arefeh
AU  - Babazadeh A
AD  - Infectious Diseases and Tropical Medicine Research Center, Health Research 
      Institute, Babol University of Medical Sciences, Babol, Iran.
FAU - Alizadeh-Khatir, Ali
AU  - Alizadeh-Khatir A
AD  - Mobility Impairment Research Center, Health Research Institute, Babol University 
      of Medical Sciences, Babol, Iran.
FAU - Sio, Terence T
AU  - Sio TT
AD  - Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, USA.
FAU - Taghizadeh Moghadam, Mohamad Ali
AU  - Taghizadeh Moghadam MA
AD  - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Tavakolli Pirzaman, Ali
AU  - Tavakolli Pirzaman A
AD  - Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
FAU - Mojadad, Ahmadreza
AU  - Mojadad A
AD  - Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
FAU - Hosseinzadeh, Rezvan
AU  - Hosseinzadeh R
AD  - Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
FAU - Barary, Mohammad
AU  - Barary M
AUID- ORCID: 0000-0001-8733-9370
AD  - Student Research Committee, Virtual School of Medical Education and Management, 
      Shahid Beheshti University of Medical Sciences, Tehran, Iran. 
      m.barary@mubabol.ac.ir.
AD  - Students' Scientific Research Center (SSRC), Tehran University of Medical 
      Sciences, Tehran, Iran. m.barary@mubabol.ac.ir.
FAU - Ebrahimpour, Soheil
AU  - Ebrahimpour S
AD  - Infectious Diseases and Tropical Medicine Research Center, Health Research 
      Institute, Babol University of Medical Sciences, Babol, Iran. 
      drsoheil1503@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221116
PL  - Italy
TA  - Acta Neurol Belg
JT  - Acta neurologica Belgica
JID - 0247035
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Humans
MH  - COVID-19 Vaccines
MH  - *COVID-19
MH  - Disease Progression
MH  - *Encephalomyelitis, Acute Disseminated
MH  - *Facial Paralysis
MH  - *Guillain-Barre Syndrome
PMC - PMC9668235
OTO - NOTNLM
OT  - Adverse event
OT  - COVID-19
OT  - Neurologic
OT  - SARS-CoV-2
OT  - Vaccine
COIS- Terence T. Sio reports that he provides strategic and scientific recommendations 
      as a member of the Advisory Board and speaker for Novocure, Inc. and also as a 
      member of the Advisory Board to Galera Therapeutics, which are not in any way 
      associated with the content or disease site as presented in this manuscript. All 
      other authors have no relevant financial interests to be declared.
EDAT- 2022/11/18 06:00
MHDA- 2023/02/25 06:00
PMCR- 2022/11/16
CRDT- 2022/11/17 10:43
PHST- 2022/03/17 00:00 [received]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/11/18 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2022/11/17 10:43 [entrez]
PHST- 2022/11/16 00:00 [pmc-release]
AID - 10.1007/s13760-022-02137-2 [pii]
AID - 2137 [pii]
AID - 10.1007/s13760-022-02137-2 [doi]
PST - ppublish
SO  - Acta Neurol Belg. 2023 Feb;123(1):9-44. doi: 10.1007/s13760-022-02137-2. Epub 
      2022 Nov 16.